Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 1 von 4
Lipids, 1993-07, Vol.28 (7), p.631-636
1993
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Phospholipid molecular species from human placenta lipids
Ist Teil von
  • Lipids, 1993-07, Vol.28 (7), p.631-636
Ort / Verlag
Berlin/Heidelberg: Springer‐Verlag
Erscheinungsjahr
1993
Quelle
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
Beschreibungen/Notizen
  • The phospholipid molecular species from a large‐scale preparation of human placenta lipids were analyzed. The major placental phospholipids were choline glycerophospholipids (CPL) (53.2 wt%), sphingomyelin (21.7 wt%) and ethanolamine glycerophospholipids (EPL) (14.6 wt%). 1,2‐Diacyl‐glycerophosphocholine was the most abundant subclass of CPL (91.7 mol%), while EPL contained 1,2‐diacyl (54.6 mol%) and 1‐alk‐1′‐enyl‐2‐acyl (43.8 mol%) subclasses. The level of polyunsaturated fatty acids (PUFA) in total phospholipids was remarkably constant (38.4–39.9 mol%) within all placental batches tested. The long‐chain PUFA, mainly 20∶4n−6 and 22∶6n−3 of the n−6 and n−3 series, respectively, were found in high proportion in all phospholipid classes, especially in EPL (46.7 mol%) and in inositol glycerophospholipids (IPL) (39.9 mol%). CPL and serine glycerophospholipids were much richer in 18∶1n−9 and 18∶2n−6. High levels of molecular species with arachidonic acid in thesn‐2 position were found particularly in 1‐alk‐1′‐enyl‐2‐acyl‐glycerophospho‐ethanolamine (with 24.0 mol% 16∶0 and 22.0 mol% 18∶0 insn‐1 position) and in 1,2‐diacyl glycerophosphoinositol with 42.6 mol% 18∶0 insn‐1 position. EPL subclasses were rich in 22∶6n−3, which occurs mainly as 16∶0/22∶6n−3 (11.7 mol%) in the polasmalogen form and as 18∶0/22∶6n−3, 16∶0/22∶6n−3 and 18∶1/22∶6n−3 in the diacyl forms. Based on their availability and composition, placental phospholipids could be of interest, for example, for supplementing artificial milk preparations with n−3 and n−6 long‐chain PUFA for newborn infants with insufficiently developed 18∶2n−6 and 18∶3n−3 desaturation/elongation.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX